In cellular assays, both ARQ 092 and/or ARQ 751 potently inhibited elevated AKT activity and showed pathway knockdown in cancer cell lines driven by PIK3CAH1047R, PTEN null, and AKT1-E17K mutations. This evidence concerns the gene AKT1 and cancer.